MedTrace Logo

Study of Cannabidiol (CBD) in Healthy Volunteers

NCT06286839 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2024-02-29

No results posted yet for this study

Summary

This was a prospective, single-centre, open label, randomized, two-arm, parallel design study to evaluate the effect of four-weeks consumption of active study product on primary endpoint in healthy adults

Conditions

  • Immune System and Related Disorders
  • Immune System Diseases

Interventions

DIETARY_SUPPLEMENT

Cannabidiol (CBD)

Cannabidiol (CBD), a non-psychoactive component of Cannabis sativa L.

Sponsors & Collaborators

  • Atlantia Food Clinical Trials

    collaborator INDUSTRY

  • NextEvo Inc.

    lead INDUSTRY

Principal Investigators

  • Alice Eggleston · Atlantia Clinical Trials

  • David Chernoff, MD · NextEvo Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-05-12
Primary Completion
2022-10-28
Completion
2022-12-14

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06286839 on ClinicalTrials.gov